Selected Publications

Christopher Pleyer, Emily Tomasulo, et. al: Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia Blood Supplement : 2024.

Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael Fradley, and Stephen J. Schuster: Resolution of ibrutinib-associated hypertension with transition to alternate covalent BTKi Blood Supplement : 2024.

Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun: Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL Leukemia & Lymphoma 64 (14): 2023.

Itsara A, Sun C, Bryer E, et al.: Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study Blood Supplement : 2023.

Emily Tomasulo: Chronic Lymphocytic Leukemia Chapter Bethesda Handbook of Hematology : 2023.

Bryer E, Itsara A, Ahn I et al.: Ibrutinib-associated sudden death in patients with CLL Blood 140 (Supplement 1): 2022.

Bryer EJ, Destefano C, Kazandjian D.: Current and prospective antibody-based therapies in multiple myeloma Semin Oncol 49 (1): 41-47,2022.

Bryer EJ, Stein E, Goldberg S.: Multivessel Coronary Artery Disease Mayo Clinic Proceedings: Innovations, Quality, and Outcomes. : 2020.

Bryer E, Dew A, Hill E, et al.: A phase II pilot study of avelumab in combination with hypofractionated radiotherapy in patients with relapsed refractory multiple myeloma Blood 136 (Supplement 1): 2020.

Bryer EJ, Kallan MJ, Chiu TS.: A Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy- Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration. EJHaem 1 (1): 35-43,2020.

Academic Contact Information

230 W Washington Square
Philadelphia, PA 19106
Patient appointments: 800-789-7366